Form 4: VolitionRx Executive Receives Stock Award in Lieu of Cash Compensation

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, received 40,709 restricted stock units (RSUs) in lieu of cash compensation on June 1, 2024.

Summary

• On June 1, 2024, Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRx Ltd, was granted 40,709 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three installments: 13,570 units on June 1, 2024, 13,570 units on July 1, 2024, and 13,569 units on August 1, 2024.
• The RSUs are also subject to further time-based vesting in a single installment on May 1, 2025, contingent upon continued service.
• Upon vesting and settlement, Micallef will receive shares of common stock equal to the number of vested RSUs.
• Micallef also indirectly owns 55,000 shares of common stock through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Positives

• The award of RSUs aligns the executive's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• Using RSUs instead of cash preserves the company's cash reserves.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning executive interests with company performance.
• Employees may see the RSU grant as a standard part of executive compensation.

Key Dates